Skip to content
HowShorted

Virpax Pharmaceuticals, Inc. short interest in 2023

In 2023, Virpax Pharmaceuticals, Inc.'s disclosed short interest ran from 0.29% of shares outstanding on 13 Jan 2023 to 0.14% on 15 Dec 2023, a change of -0.15 percentage points. The year's high was 0.90% on 15 May 2023 and its low 0.14% on 15 Sep 2023, averaging 0.47% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.66 days on 28 Apr 2023. Full history: Virpax Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for Virpax Pharmaceuticals, Inc. in 2023

2023 in figures

Start of year
0.29% (13 Jan 2023)
End of year
0.14% (15 Dec 2023)
Change
-0.15 pp
High
0.90% (15 May 2023)
Low
0.14% (15 Sep 2023)
Average
0.47%
Highest days to cover
6.66 (28 Apr 2023)
SEC filings marked
8

Every report in 2023

Virpax Pharmaceuticals, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20230.29%1.00
31 Jan 20230.29%1.00
28 Feb 20230.68%2.62
15 Mar 20230.72%5.18
31 Mar 20230.78%5.3110-K filed, results (8-K)
14 Apr 20230.72%4.96
28 Apr 20230.74%6.66
15 May 20230.90%4.7710-Q filed, results (8-K)
31 May 20230.66%5.00
15 Jun 20230.43%1.70
30 Jun 20230.68%1.00
14 Jul 20230.35%1.77
31 Jul 20230.36%1.93
15 Aug 20230.29%1.3910-Q filed, results (8-K)
31 Aug 20230.22%1.19
15 Sep 20230.14%1.00
13 Oct 20230.24%1.00
31 Oct 20230.51%3.66
15 Nov 20230.47%3.42
30 Nov 20230.33%1.00results (8-K)
15 Dec 20230.14%1.0010-Q filed

See also: Virpax Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.